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Abstract
Background
Irritable bowel syndrome (IBS), a chronic functional condition, considerably reduces quality
of life (QoL) and referral to gastroenterology is common. Until now, however, the impact of
seeing a gastroenterologist for IBS on patients’QoL and utility has not been assessed.
Methods
Patients referred with “probable IBS” to the Nottingham Treatment Centre between October
2012 and March 2014 were invited to complete a QoL questionnaire (EuroQol–5 Dimen-
sion) before their first appointment. Patients with confirmed IBS who completed this base-
line assessment were sent follow-up questionnaires three and twelve months later. Global
QoL and utility were measured at each time point and change from baseline calculated.
Paired t-tests analysed the significance of any change.
Results
Of 205 invited patients, 69 were eligible and recruited. Response at three and twelve
months was 45% and 17% respectively. Median global QoL at baseline was 67.5 (Interquar-
tile range [IQR] 50.0 to 80.0), with a mean increase of 3.25 (95% confidence interval [CI]
-5.38 to 11.88) three months later and a mean decrease of -1.82 (95% CI -16.01 to 12.38)
after one year. The median utility at baseline was 0.76 (IQR 0.69 to 0.80), with a mean
increase of 0.06 (95%CI -0.01 to 0.14) at three months and no change, 0.00 (-0.16 to 0.16),
after one year.
Conclusion
Patients experienced a small but not statistically significant increase in QoL and utility three
months after seeing a gastroenterologist for IBS, which was not maintained. Gastroenterol-
ogy referral does not appear to appreciably improve Qol for most people with IBS.
PLOS ONE | DOI:10.1371/journal.pone.0139389 October 2, 2015 1 / 13
a11111
OPEN ACCESS
Citation: Canavan C, West J, Card T (2015) Change
in Quality of Life for Patients with Irritable Bowel
Syndrome following Referral to a Gastroenterologist:
A Cohort Study. PLoS ONE 10(10): e0139389.
doi:10.1371/journal.pone.0139389
Editor: Delphine S. Courvoisier, University of
Geneva, SWITZERLAND
Received: June 15, 2015
Accepted: September 11, 2015
Published: October 2, 2015
Copyright: © 2015 Canavan et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: Fully anonymised
EQ5D responses in each round, with sex and age
group data is available online through the open
access repository Dryad, doi:10.5061/dryad.qg87n.
Funding: This study was funded through a UK
Medical Research Council Population Health
Scientist Fellowship awarded to CC, award number
G1002360.
Competing Interests: The authors have declared
that no competing interests exist.
Abbreviations: CI, Confidence interval; EQ-5D,
EuroQol–5 Dimensions questionnaire; IBS, irritable
Background
Irritable Bowel Syndrome (IBS) is a chronic condition characterised by abdominal pain with
associated diarrhoea, constipation or both but with no structural abnormality of the bowel. IBS
has no attributable mortality[1] but it is important due to the effect it has on quality of life
(QoL)[2,3] and the large number of people it effects, with a global prevalence of 11%.[4]
IBS causes considerable reductions in all dimensions of QoL.[2] The effects on work, social
life and ability to travel are the greatest[5,6] and most IBS patients report at least moderate
pain and moderate anxiety or depression.[5–8] Symptoms fluctuate over time, but QoL does
not change over three months without any intervention.[9,10] This morbidity leads to high lev-
els of health care utilization,[9,11–16] with over half of primary care consultations for IBS
being because the patient is not satisfied with their previous treatment.[13] This dissatisfaction
is the principle reason primary care physicians refer patients with IBS to see a gastroenterolo-
gist.[17] Uncertainty that IBS is the correct diagnosis is the second most frequent reason.[17]
This uncertainty seems most common when patients have diarrhoea predominant symptoms.
[18,19] Consequently, despite guidelines recommending a positive clinical diagnosis and man-
agement in primary care,[20] around 20% of IBS patients see a gastroenterologist.[12,19] Some
studies have assessed how successful seeing a gastroenterologist is for confirming the IBS diag-
nosis,[21–23] but none have addressed how it affects QoL, the most frequent reason for the
referral.[17]
Consequently, we conducted this study to measure how consulting a gastroenterologist for
IBS affects QoL. This information is essential to enable clinicians to make appropriate referral
decisions and for healthcare commissioners and decision makers to optimise resource
allocation.
Methods
We screened referral letters from general practitioners to the gastroenterology outpatient clinic
at the Nottingham Treatment Centre between October 2012 and March 2014 to identify
patients likely to have IBS. We excluded patients with previous secondary care attendance for
their symptoms mentioned in their referral letters. Potentially eligible patients with referral let-
ters describing symptoms in keeping with a diagnosis of IBS, or who had IBS diagnosed already
by the general practitioner were sent a QoL questionnaire before seeing a gastroenterologist.
The questionnaire consisted of the EuroQol Questionnaire of 5-Dimensions (EQ-5D) and
some supplementary questions that asked about demographics, symptoms, time off work and
asked patients to confirm this was their first attendance at a gastroenterology clinic. The QoL
data from this instrument is converted easily to a utility score on a scale from 0 (death) to 1
(perfect health) which is necessary for use in economic evaluation. EQ-5D has also been shown
to be valid in IBS, it is sensitive to change in disease captured on disease specific instruments[5]
and has good longitudinal validity.[24] If patients wished to participate, they completed the
questionnaire before attending for their appointment and brought it with them. Final diagnosis
of IBS was confirmed by checking participants’ medical records eight to ten weeks following
their clinic appointment. Those found not to have IBS were then withdrawn from the study.
Participants with confirmed IBS were sent a second questionnaire three months following their
first appointment. A third questionnaire was sent to all the eligible participants one year after
their initial clinic appointment, regardless of whether they returned the second questionnaire.
Exclusion criteria
We did not invite patients aged under 16 or currently inmates in a prison to take part in the
study. Patients who declined to participate, were unable to consent, had not completed the first
QoL in IBS before and after GI Appointment
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questionnaire adequately to assess EQ-5D (including for reasons of illiteracy in written
English) or did not attend the appointment were not recruited. Recruits were excluded from
the study if they were diagnosed with a condition other than IBS following their clinic appoint-
ment or the clinic appointment was not their first referral for their IBS symptoms. Participants
who returned invalid second or third questionnaires had that questionnaire excluded and were
sent a replacement.
Statistics
The EQ-5D health state utility value was calculated using the UK specific valuation algorithm.
[25] Baseline characteristics were analysed using simple descriptive statistics. The mean differ-
ence in utility, VAS and time off work for each patient before their clinic appointment and at
three and twelve months afterwards were analysed using paired t-tests with 95% confidence
intervals. We stratified VAS and utility results by sex, age, whether the person had a diagnosis
of IBS before they were referred and by the underlying symptoms causing the referral (pain,
diarrhoea, constipation or alternating bowel habit). Mean difference from before seeing a
gastroenterologist to three and twelve months afterwards was calculated with 95% confidence
intervals and significance assessed using paired t-tests.
Ethics approval was granted by the East Midlands Regional Ethics Committee (code: 11/
EM/0298).
Results
We invited 205 patients to participate after screening referral letters. Of these, sixty declined,
31 did not have an initial questionnaire collected before their appointment as required in our
protocol and 22 did not meet the eligibility criteria. Ninety-two patients completed the first
questionnaire. Review of their notes after the appointment found that 5 had been seen previ-
ously by gastroenterologist and 18 were not diagnosed with IBS. This left 69 patients with IBS
referred to see a gastroenterologist for the first time who were recruited to our study. At three
months, 29 (42%) returned a follow-up questionnaire and at one year 12 (17%) returned a fur-
ther questionnaire (Fig 1). Table 1 shows the demographic details of all invited patients, the ini-
tial recruits and the responders at each time point. From those invited, 41% of referrals already
had a diagnosis of IBS and over half were referred with diarrhoea. Over two thirds of the
patients were female, with 73% of those invited and 69% of responders being female. The mean
age of all invited patients was 41.4 years (95% CI 39.3 to 43.6) and the mean age of those partic-
ipating was 40.2 years (95% CI 37.2 to 43.3). The proportions of patients in each age group dif-
fered between those invited and the participant sample, with the young somewhat
underrepresented amongst participants. Twenty-percent of the responders were diagnosed
with a condition other than IBS following their clinic appointment and investigations
(Table 2). Of these patients, 35% (8 patients) had a previous diagnosis of IBS. Referral symp-
toms in those diagnosed with something other than IBS were proportionate to the total sample
invited (Table 1).
QoL domains
Participants reported that pain or discomfort and depression or anxiety were the two domains
that contributed to the greatest loss of QoL at each time point (Table 3). Only 17% reported no
problems with pain before they saw a gastroenterologist, this increased to 38% at three months,
but fell again to 17% at one year. Across the three questionnaires, around 8% reported extreme
pain or discomfort and around 10% reported extreme depression or anxiety. No participants
QoL in IBS before and after GI Appointment
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Fig 1. Flowchart showing the recruitment process.
doi:10.1371/journal.pone.0139389.g001
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reported extreme problems with mobility, self-care or activities of daily living at any time point
(Table 3).
Overall utility
The median overall utility score for the cohort before seeing a gastroenterologist was 0.76
(Interquartile range [IQR] 0.69 to 0.80). Three months after the gastroenterology appointment,
44% had improved utility, 42% experienced no change and 14% had worse utility (Fig 2). The
mean utility increased by 0.04 to 0.80 (IQR 0.62 to 1.00). One year after the appointment, a
third of responders had improved utility from the baseline, a third experienced no change and
a third had worse utility (Fig 2). The mean utility fell by 0.07 from the 3 month peak to 0.73
(IQR 0.65 to 0.76), a 0.04 decrease from the pooled baseline. None of these changes were statis-
tically significant, however. When responses at three and twelve months were compared to the
baseline response of the same patients, as opposed to the whole cohort initially recruited, the
mean utility three months after seeing a gastroenterologist had increased by 0.06 (95% CI -0.01
to 0.14), but this change reduced to 0.00 (95% CI -0.16 to 0.16) after a year (Table 4). When the
results were stratified, the two groups who showed sustained increased utility were those aged
Table 1. Demographics of all patients invited to participate in this study, those who agreed to participate, those diagnosed with something other
than IBS and the responders in each round who contributed the questionnaires to the analysis.
All invited
patients referred
potentially with
IBS
Patients who
declined to
participate
Responders to baseline
questionnaire before GI
appointment
Responders to second
questionnaire 3
months after GI
appointment
Responders to third
questionnaire 12
months after GI
appointment
Total Excluded Eligible
Total 205 113 92 23 [18 not
IBS]
69 29 12
Percent of all invited 100% 55% 45% 11% 34% 14% 6%
Percent of all initial
responders
- - 100% 25%
[19.6% not
IBS]
75% 32% 13%
Percent of eligible
participants
- - - - 100% 42% 17%
Sex (%) Male 55 (26.8) 25 (22.1) 30
(32.6)
9 (39.1) 21
(30.4)
9 (31.0) 3 (25.0)
Female 150 (73.2) 88 (77.9) 62
(67.4)
14 (60.9) 48
(69.6)
20 (69.0) 9 (75.0)
Age group
(%)
18–29 58 (28.3) 27 (23.9) 31
(33.7)
4 (17.4) 27
(39.1)
11 (37.9) 5 (41.7)
30–49 82 (40.0) 46 (40.7) 36
(39.1)
11 (47.8) 25
(36.2)
10 (34.5) 2 (16.6)
Over 50 65 (31.7) 40 (35.4) 25
(27.2)
8 (34.8) 17
(24.6)
8 (27.6) 5 (41.7)
Diagnosed with IBS before
GI referral (%)
84 (41.0) 44 (38.9) 40
(43.5)
8 (34.8) 32
(46.4)
11 (37.9) 6 (50.0)
Reason
for referral
(%)
Abdominal
pain
139 (67.8) 80 (70.8) 59
(64.1)
14 (60.9) 43
(62.3)
15 (51.7) 10 (83.3)
Diarrhoea 101 (49.3) 50 (44.3) 51
(55.4)
12 (52.2) 39
(56.5)
16 (55.2) 6 (50.0)
Constipation 26 (12.7) 18 (15.1) 8
(8.7)
4 (17.3) 4 (5.8) 1 (3.5) 3 (25.0)
Alternating
bowel habit
29 (14.2) 17 (15.0) 12
(13.0)
1 (4.3) 11
(15.9)
4 (13.8) 1 (8.3)
doi:10.1371/journal.pone.0139389.t001
QoL in IBS before and after GI Appointment
PLOS ONE | DOI:10.1371/journal.pone.0139389 October 2, 2015 5 / 13
over 50 years and those referred with diarrhoea. Men and women had similar utility at baseline,
at three months men has greater mean improvement but this was not maintained at one year.
At baseline, utility was higher in patients aged under 30. At three months those aged over 30
years reported greater mean improvement in utility which was sustained at one year, whilst
those aged under 30 reported a mean decrease in utility. None of these findings were statisti-
cally significant. No changes in utility at three or twelve months were statistically significantly
different from before seeing the gastroenterologist (Table 4). Mean values have been reported
in Table 3 to make the results amenable to future cohort modelling.
Global QoL (VAS)
Before seeing a gastroenterologist, the median VAS score for the cohort was 67.5 (IQR 50.0 to
80.0). Three months after the gastroenterology appointment, this increased to 75.0 (58.0 to
89.0), but had fallen to 60.0 (IQR 50.0 to 80.0) at one year. The mean change in VAS for indi-
viduals from before seeing a gastroenterologist to three months afterwards was not statistically
significant nor was it one year later (Table 5). Table 5 shows that men experienced greater
mean improvement in their global QoL three and twelve months after their gastroenterology
appointment. Patients referred with diarrhoea also reported greater improvement in global
QoL at both time points, whilst those referred with constipation or alternating bowel habit
reported decreased global QoL after three and twelve months. None of the changes within the
strata were statistically significant, however.
Time off work
In the month preceding the first appointment with a gastroenterologist, the median number of
days patients with IBS took off work (or away from their usual daily activities if they were not
employed) for symptoms related to IBS was zero (IQR 0 to 4). Fifty-five percent of patients
took no time off work due to their IBS and for those who did take time off the median time off
work in a month was 4 days (IQR 2 to 14). Five patients reported that their IBS meant they
were off work for the whole month. There was no statistically significant difference in the
Table 2. Conditions diagnosed by a gastroenterologist during outpatient assessment following the
first referral of patients potentially with IBS from primary care.
Condition diagnosed or conﬁrmed by
gastroenterologist
Total % of responders
IBS 74 80.4
Conditions other than IBS 18 19.6
Colorectal cancer 2 2.2
Inﬂammatory bowel disease 2 2.2
Obstructed defecation 2 2.2
Coeliac disease 1 1.1
Diverticular disease 1 1.1
Chronic abdominal pain 1 1.1
Gastroenteritis 1 1.1
Faecal incontinence 1 1.1
Rectal polyp 1 1.1
Tropical sprue 1 1.1
Non GI problem 5 5.4
doi:10.1371/journal.pone.0139389.t002
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number of days patients took off work before seeing a gastroenterologist and afterwards, either
at three or twelve months.
Discussion
This is the first study to examine the effect of gastroenterology referral on QoL of patients with
IBS. We found that in this group there was on average low initial quality of life, which
improved somewhat 3 months after consultation, but declined to baseline after a year. We also
found that in this group, who were identified as being likely to have IBS by their GPs, or from
screening letters by a gastroenterology Registrar (CC), almost 20% had another organic gastro-
intestinal diagnosis made.
Although our study is not directly comparable to any other, and so arguably gives the best
available measure of the benefit of gastroenterology referral in IBS patients, its quality needs to
be examined if our results are to be correctly interpreted. We have based our work in a large
teaching hospital where both sub-specialist neuro-gastroenterologists and more general lumi-
nal gastroenterologists cared for the recruited patients. To ensure that our results will be gener-
alisable to UK secondary care referrals we therefore excluded anyone who had previously been
seen in secondary care for their problem. To generate utility values alongside QoL measures
and ensure that our results can be compared to others in IBS as well as other conditions, we
used the generic EQ-5D questionnaire. This has been validated against the disease specific
instruments for IBS[26] and the utility scores are widely used and accepted for health economic
evaluations.[27]
Table 3. EQ-5D responses by domain andmedian and VAS scores overall utility.
Domain of EQ-5D Score Baseline before
gastroenterology
appointment for
all eligible ﬁrst
responders
(n = 69)
Baseline before
gastroenterology
appointment for
responders with a
valid 2nd or 3rd
questionnaire
(n = 32)
3 months
following
gastroenterology
appointment
(n = 29)
12 months
following
gastroenterology
appointment
(n = 12)
n % n % n % n %
1 60 87.0 28 87.5 21 72.4 11 91.7
Mobility 2 9 13.0 4 12.5 8 27.6 1 8.3
3 0 0.0 0 0.0 0 0.0 0 0.0
1 67 97.1 30 93.8 27 93.1 12 100.0
Self-care 2 2 2.9 2 6.2 2 6.9 0 0.0
3 0 0.0 0 0.0 0 0.0 0 0.0
1 43 62.3 17 53.1 17 58.6 10 83.3
Activities of daily living 2 26 37.7 15 46.9 12 41.4 2 16.7
3 0 0.0 0 0.0 0 0.0 0 0.0
1 12 17.4 7 21.9 11 37.9 2 16.7
Pain and discomfort 2 51 73.9 21 65.6 16 55.2 9 75.0
3 6 8.7 4 12.5 2 6.9 1 8.3
1 35 50.7 15 46.9 17 60.7 4 33.3
Depression and anxiety 2 26 37.7 14 43.7 8 28.6 7 58.3
3 8 11.6 3 9.4 3 10.7 1 8.3
Median overall utility score (IQR) 0.76 (0.69 to 0.80) 0.73 (0.65 to 0.78) 0.80 (0.62 to 1.00) 0.73 (0.65 to 0.76)
Mean overall utility score for economic
analysis (95% CI)
0.68 (0.62 to 0.74) 0.68 (0.59 to 0.78) 0.73 (0.62 to 0.84) 0.69 (0.55 to 0.83)
Median VAS score (IQR) 67.5 (50.0 to 80.0) 65.0 (50.0 to 84.0) 75.0 (58.0 to 89.0) 60.0 (50.0 to 80.0)
doi:10.1371/journal.pone.0139389.t003
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Our study has an obvious weakness in its response rates, however, particularly at one year.
This level of loss to follow up inevitably raises concerns about bias in the non-response.
Though we cannot exclude the possibility of bias, when examining the known characteristics of
respondents and non-respondents at each stage the groups appear similar, so such bias is at
least not obvious. Despite this, it is still possible that those who are lost to follow-up have all
been sufficiently reassured or had their management optimised following the gastroenterology
appointment resulting in considerable improvement in QoL. If this is the case, then our study
underestimates the positive impact of a referral to gastroenterology for patients with IBS. If the
mean utility change for all respondents at each time point is assessed, then utility increased by
0.04 over the first three months and then decreased by 0.07 over the next nine months, so that
it was 0.03 lower than baseline at one year. The magnitude of the increase in utility at three
months is the same when the baseline is restricted to only those responding at three months.
The magnitude of the decrease at 12 months is reduced, however. This means that the baseline
utility for those patients responding at 12 months had a lower mean than those who were lost
to follow-up. It is possible, therefore, that there is a response bias due to the respondents lower
baseline utility representing patients who are less likely to benefit from a gastoenterology
appointment. This would need further assessment in future studies. A further problem conse-
quent upon the loss to follow up is that we have very limited power. We are therefore unable to
Fig 2. Proportion of respondents reporting a change in their utility from baseline (remaining responders reported no change) at three and twelve
months with the mean utility score change and 95% confidence intervals.
doi:10.1371/journal.pone.0139389.g002
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be certain that the non-significant increase in QoL we found at 3 months is not important. In
fact, the minimum clinically important difference in utility score using the EQ-5D in IBS is
only 0.03,[26] so the 0.06 point mean increase which is our central estimate would clearly be
important if true. Yet the results at one year suggest that even if there is a real effect on QoL
three months after referral it is likely to be transient. Finally, the low power limits our ability to
assess differences in subgroups of IBS patients. Notwithstanding this, the non-significant bene-
fit we found was more pronounced in older patients with diarrhoea.
Even though there are no directly comparable studies yet published, our results should be
considered in conjunction with what is already known. In keeping with other studies that
report greater referral of patients with diarrhoea predominant symptoms rather than constipa-
tion or alternating bowel function[17,19,28], a higher proportion of patients in our study had
diarrhoea predominant IBS than is seen in primary care.[1] Likewise, almost 20% of the 92
patients who completed a first questionnaire were diagnosed with a condition other than IBS,
which is similar to a previous report in the UK.29 In that study, between 15% and 28% of simi-
lar patients undergoing colonoscopy had a diagnosis other than IBS apparently responsible for
their symptoms.[29] These results are at variance however with those from America where a
structural lesion has been reported in over 40% of patients with IBS who received a colonos-
copy.[21] The proportion with such lesions, however, was not significantly different to that
found in screening colonoscopy in the general population and only changed the diagnosis of
IBS in 2% of patients.[21] In contrast to the higher American prevalence of apparent organic
disease, in Denmark organic disease was identified in only 10% of patients diagnosed with IBS
Table 4. Median overall utility score at each time point stratified by demographic variables, with mean difference from baseline and the p-value
from a paired t-test. Clinically significant mean changes are in bold. No results were statistically significant at the 5% level.
Median before
gastroenterology
appointment [IQR]
Median three
months
afterwards
[IQR]
Mean
difference
from baseline
at 3 months
[95% CI]
p-value for
mean
difference
Median
twelve
months
afterwards
[IQR]
Mean
difference
from baseline
at 12 months
[95% CI]
p-value for
mean
difference
Patients
with 3
month
follow-up
Patients
with 12
month
follow-up
Total 0.73 [0.62,
0.80]
0.71 [0.62,
0.80]
0.80 [0.62,
1.00]
0.06 [-0.01,
0.14]
0.10 0.73 [0.65,
0.76]
0.00 [-0.16,
0.16]
0.98
Sex Male 0.73 [0.62,
0.80]
0.62 [0.19,
0.62]
0.80 [0.69,
1.00]
0.11 [-0.02,
0.23]
0.10 0.62 [0.26,
1.00]
-0.02 [-0.13,
0.08]
0.42
Female 0.74 [0.65,
0.80]
0.76 [0.69,
0.80]
0.80 [0.62,
1.00]
0.04 [-0.06,
0.14]
0.39 0.73 [0.73,
0.73]
0.00 [-0.22,
0.23]
0.96
Age
group
18–29 0.80 [0.19,
0.88]
0.69 [0.19,
0.77]
0.69 [0.26,
0.88]
-0.01 [-0.16,
0.14]
0.88 0.73 [0.69,
0.73]
-0.07 [-0.43,
0.30]
0.64
30–49 0.71 [0.52,
0.80]
0.74 [0.69,
0.80]
0.82 [0.69,
1.00]
0.13 [-0.01,
0.27]
0.06 0.73 [0.73,
0.73]
0.02 [-0.66,
0.70]
0.80
Over 50 0.74 [0.65,
0.80]
0.76 [0.73,
0.80]
0.80 [0.67,
1.00]
0.07 [-0.05,
0.19]
0.20 0.73 [0.62,
1.00]
0.05 [-0.30,
0.40]
0.70
Diagnosed with IBS
before GI referral
0.73 [0.52,
0.80]
0.74 [0.70,
0.80]
0.73 [0.52,
1.00]
0.06 [-0.01,
0.13]
0.07 0.73 [0.73,
0.73]
0.01 [-0.17,
0.20]
0.88
Reason
for
referral
Abdominal
pain
0.73 [0.19,
0.80]
0.76 [0.69,
0.80]
0.80 [0.26,
1.00]
0.04 [-0.07,
0.15]
0.48 0.73 [0.69,
0.80]
-0.01 [-0.21,
0.20]
0.94
Diarrhoea 0.72 [0.60,
0.80]
0.80 [0.76,
1.00]
0.74 [0.60,
0.94]
0.03 [-0.08,
0.15]
0.55 0.73 [0.29,
0.80]
0.12 [-0.11,
0.36]
0.23
Constipation
or Alternating
0.73 [0.62,
0.80]
0.69 [0.44,
0.74]
0.85 [0.62,
1.00]
0.15 [-0.07,
0.37]
0.13 0.73 [0.71,
0.73]
-0.12 [-0.56,
0.31]
0.43
doi:10.1371/journal.pone.0139389.t004
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who subsequently received extensive gastroenterological investigation.[23] In the Danish
study, however, patients were randomly assigned gastroenterological investigation as opposed
to having been referred for further investigation as in our own.
Across Europe and North America utility values between 0.62 and 0.75 have been reported
by patients with IBS[5,7,10,30] (equivalent to an average patient being willing to sacrifice
between 10 and 15 years of their remaining life expectancy for an immediate cure[10]). Our
baseline findings are comparable, with a median EQ-5D utility value of 0.76 (0.69 to 0.80). This
is 0.10 points lower than the UK population average,[31] consistent with the reduction previ-
ously reported in IBS.[5,30] In our study, only 74% of patients had at least some pain at refer-
ral. This might seem low given that the presence of pain is required to meet the Rome III
criteria. It is however slightly higher than a previous UK community based study in which only
two-thirds reported some pain,[8] perhaps suggesting that complaints of pain affecting QoL
increase the likelihood of referral. Pain was less common in a recent study of patients referred
to a gastroenterologist with functional gastrointestinal conditions,[28] though the inclusion of
conditions not requiring pain for diagnosis could clearly affect this result. Our finding that
almost half experienced at least moderate depression and anxiety was the same as found in the
UK community study.[8]
Despite the UK National Institute for Health and Clinical Excellence (NICE) recommend-
ing the measurement of utilities using the EQ-5D[27] for health care decision making, there
are very few studies that have reported health utilities in IBS using the EQ-5D. Current guide-
lines are therefore based on models calculated from assumed utility changes.[20] Since these
Table 5. Median overall VAS score at each time point stratified by demographic variables, with mean difference from baseline and the p-value
from a paired t-test for significance of the mean change.
Median before
gastroenterology
appointment [IQR]
Median three
months
afterwards
[IQR]
Mean
difference
from baseline
at 3 months
[95% CI]
p-value for
mean
difference
Median
twelve
months
afterwards
[IQR]
Mean
difference
from baseline
at 12 months
[95% CI]
p-value for
mean
difference
Patients
with 3
month
follow-up
Patients
with 12
month
follow-up
Total 65.7 [55.0,
85.0]
62.5 [50.0,
80.0]
75.0 [58.0,
89.0]
3.25 [-5.38,
11.88]
0.45 60.0 [50.0,
80.0]
-1.82 [-16.01,
12.38]
0.78
Sex Male 80.0 [60.0,
90.0]
60.0 [50.0,
90.0]
84.0 [75.0,
90.0]
4.33 [-10.19,
18.85]
0.51 40.0 [20.0,
60.0]
15 [-30.24,
33.26]
0.65
Female 65.0 [50.0,
84.0]
70.0 [55.0,
80.0]
72.5 [54.0,
87.0]
2.74 [-8.90,
14.37]
0.63 60.0 [60.0,
80.0]
-1.11 [-15.46,
13.24]
0.86
Age
group
18–29 70.0 [60.0,
84.0]
60.0 [25.0,
70.0]
69.0 [50.0,
85.0]
0.00 [-7.41,
7.41]
1.00 60.0 [30.0,
60.0]
-1.00 [-35.69,
33.68]
0.94
30–49 65.0 [40.0,
86.0]
72.5 [55.0,
90.0]
81.5 [75.0,
93.0]
12.4 [-8.13,
32.93]
0.21 75.0 [70.0,
80.0]
-2.50 [-16.13,
15.63]
0.87
Over 50 65.0 [50.0,
90.0]
80.0 [65.0,
90.0]
75.0 [55.0,
87.0]
-4.71 [-26.2,
17.09]
0.62 60.0 [55.0,
75.0]
7.50 [-18.89,
33.89]
0.43
Diagnosed with IBS
before GI referral
63.0 [50.0,
90.0]
72.5 [55.0,
90.0]
79.0 [50.0,
90.0]
0.70 [-15.67,
17.06]
0.93 75.0 [60.0,
90.0]
-2.50 [-13.38,
8.38]
0.58
Reason
for
referral
Abdominal
pain
65.5 [60.0,
80.0]
75.0 [55.0,
90.0]
69.0 [50.0,
84.0]
-1.71 [-13.53,
10.10]
0.76 60.0 [50.0,
80.0]
2.78 [-15.05,
20.61]
0.73
Diarrhoea 63.0 [60.0,
82.0]
75.0 [65.0,
80.0]
75.0 [60.0,
87.5]
7.68 [-3.03,
18.41]
0.15 60.0 [50.0,
60.0]
15.00 [-9.83,
39.83]
0.17
Constipation
or Alternating
80.0 [50.0,
80.0]
40.0 [22.5,
72.5]
84.0 [50.0,
85.0]
-2.20 [-33.73,
29.33]
0.86 65.0 [45.0,
75.0]
-12.50 [-41.91,
16.91]
0.27
doi:10.1371/journal.pone.0139389.t005
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guidelines were published there have however been some studies reported of utility change fol-
lowing interventions in patients with IBS.[32–35] Only one of these found a change in utility
which was both clinically meaningful and statistically significant, and that was from the use of
a serotonin-receptor partial agonist in patients with constipation predominant IBS.[32] All the
other studies like our own have been unable to demonstrate such changes,[33–35] perhaps sug-
gesting that few if any available interventions improve global QoL or overall utility in patients
with IBS.[36]
Summary and conclusions
In an era of health austerity, it will be increasingly necessary to demonstrate the efficacy of our
care. We have shown a small, non-significant, but potentially clinically meaningful mean
increase in QoL for IBS patients three months after seeing a gastroenterologist. This improve-
ment was not maintained at one year, however. Although larger studies, in particular rando-
mised control trials, of this complex intervention may in future provide better evidence, at
present the most important benefit from referral that we have been able to demonstrate may be
the diagnosis of other organic pathology. Until better data are available however, the figures we
provide now permit some assessment of the cost/utility of referring patients with IBS to gastro-
enterology services.
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